August 24, 2005 HOT TOPICS NEWS & INFORMATION: TOOLS FOR: RESOURCES:  >  > Attention Business Editors: Allon begins dosing in Phase I human trial of second product for mild cognitive impairment VANCOUVER, Aug. 22 /CNW/ - Allon Therapeutics Inc. (TSX-V:"NPC"), The Neuro Protection Company(TM), announced today it has commenced dosing the first patient in a Phase I human clinical trial to evaluate the Company's second product AL-208 as an intravenous treatment for mild cognitive impairment (MCI) associated with post-coronary artery bypass graft (CABG) surgery. Clinical drug development experts estimate this market to be $3 billion for which there is no available treatment today. Gordon McCauley, President and CEO of Allon, said the Phase I trial is administering AL-208 to 48 healthy adults randomized into six dose groups to evaluate its safe

more...